Cynomolgus AGER Protein


Cat. No. AER-CM101

κλιτυς

Recombinant Cynomolgus AGER Protein is expressed from HEK293 with His tag at the C-Terminus.
It contains GIn24-Thr354.
A0A2K5TSM4
The protein has a predicted MW of 36.78 kDa. Due to glycosylation, the protein migrates to 50-65 kDa based on Tris-Bis PAGE result.
Less than 1EU per μg by the LAL method.
> 95% as determined by Tris-Bis PAGE
age
Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt20 to -80°C for 3-6 months in unopened state after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
The receptor for advanced glycation end products (AGER) is an oncogenic transmembranous receptor up- regulated in various human cancers. AGER promotes proliferation, migration, and inhibits apoptosis of squamous cervical cancer and might function as a tumor promoter in cervical cancer. Our study provides novel evidence for a potential role of AGER in bridging human papillomavirus (HPV)-induced inflammation and cervical cancer.

Assay Data

Tris-Bis PAGE



Cynomolgus AGER on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.